COMPOSITION
Tekazon 4 mg Injectabale Solution is a transparent, clear, sterile solution, Each ml contains dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone, 1 mg of methyl parahydroxybenzoate (E 218), 0.1 mg of propyl parahydroxybenzoate (E 216) and 1.44 mg of sodium metabisulfite (E 223) as preservatives.
INDICATIONS FOR USE
Dog:
In the treatment of inflammation, allergy and shock,
Goat:
In the treatment of inflammation, allergy and shock,
In the treatment of primary ketosis (pregnancy toxemia),
Cattle:
In the treatment of inflammation, allergy and shock,
In the treatment of primary ketosis,
At the initiation of labor,
Horse:
Osteoarticular inflammations (arthritis, bursitis or tenosynovitis)
In the treatment of inflammation, allergy and shock.
USAGE AND DOSAGE
As an anti-inflammatory or in allergic conditions; It is administered as a single intramuscular injection at the following doses. In the treatment of primary ketosis in cattle; 0.02-0.04 mg/kg dexamethasone (1-2 ml of product per 200 kg of body weight) is administered intramuscularly in a single dose. In cases of persistence or recurrence of symptoms, an upper limit dose (0.04 mg/kg) may be required. Care should be taken not to overdose on the Channel Island breed.
For the initiation of birth in cattle;
From the 260th day of pregnancy, a single dose of 5 ml is administered intramuscularly. Labor should begin at 48-72 hours after the application.
For the treatment of arthritis, bursitis or tenosynovitis in horses;
It is administered intra-articular 0.5-2.5 ml.
This amount is for guidance only the dosage should be determined by the veterinarian In intra-articular or intra-bursa applications, fluid should be withdrawn as much as the application amount from the application site. The rules of asepsis must be followed at the highest level.
Aseptic rules must be followed in all applications. For doses less than one ml, A suitable syringe should be used to accurately dose less than one ml.
WITHDRAWAL PERIOD(S)
During treatment and within 8 days after the last drug application, goats and cattle should not be sent for slaughter. In cows from which milk for human consumption is obtained, milk should not be offered for human consumption during the treatment and within 72 hours (6 milkings) after the last drug application. It is not used in goats from which milk for human consumption is obtained.
MARKETING PACKAGING
It is offered in 20, 50 and 100 ml type II amber colored glass vials closed with a bromobutyl rubber stopper and a aluminum flip-off cap in a cardboard box.
